Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 (USP17L1) is a cysteine-type deubiquitinating enzyme that removes ubiquitin from conjugated proteins to regulate cellular functions such as protein stability, cell proliferation, the cell cycle, apoptosis, cell migration, and response to viral infection[2][3]. It belongs to the ubiquitin-specific protease family, whose members influence cellular homeostasis by recycling ubiquitin and modulating the degradation and function of numerous protein substrates. Evidence for direct disease association, biomarkers, or drug interactions specific to USP17L1 is currently lacking, but the family is broadly studied in cancer biology and infection. USP17L1 is predicted to localize to the cytosol, nucleus, and endoplasmic reticulum, reflecting roles in diverse intracellular processes[2].
Inhibition of deubiquitinating activity (theoretical; no known drugs) Modulation of cell cycle regulation, apoptosis, and protein stability via effects on ubiquitin removal
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 (USP17L1).